Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV001420520 | SCV001622821 | uncertain significance | Developmental and epileptic encephalopathy, 51 | 2020-05-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002377664 | SCV002683830 | uncertain significance | Inborn genetic diseases | 2021-12-01 | criteria provided, single submitter | clinical testing | The p.E300G variant (also known as c.899A>G), located in coding exon 9 of the MDH2 gene, results from an A to G substitution at nucleotide position 899. The glutamic acid at codon 300 is replaced by glycine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |